Orcosa

Company

Medicines designed around people.

We are a clinical-stage pharmaceutical company developing our own medicines with RITe™, our proprietary tablet technology.

Our purpose is simple.
The work is multidisciplinary.

We believe the way a medicine is taken deserves as much thought as the medicine itself.

That belief shapes how we formulate RITe™ tablets and advance our medicines. Throughout development, we consider the experience of the person who will take them.

Our team brings together pharmaceutical development, clinical experience, operations, finance, law, and people strategy.

Formulation & development

In-house capabilities connect dosage-form design with analytical and manufacturing work.

Clinical investigation

Clinical research informing the advancement of our medicines.

Intellectual property

Our platform and product portfolio are supported by multiple patents granted internationally, with many additional patents pending, alongside proprietary formulation and manufacturing know-how.

Grandfather watching his young grandson draw with crayons at a sunlit table.
Older woman talking with a younger woman whose hand rests on her shoulder.
Two smiling girls with their arms around one another against a pink background.
Man in a navy jacket standing beside a coral-colored building.

Our perspective

People give our work
its purpose.

From childhood through later life, people experience taking medicine differently. We keep those everyday experiences in view as we develop our medicines.

Our team brings the care and focus of a small pharmaceutical company to a shared ambition: modernizing the way medicines are taken.

Leadership & expertise

The people behind Orcosa.

Bryan Ridall

Co-Founder & Chief Executive Officer

Leading Orcosa’s vision, strategy, and development priorities.

Vincent T. Mileto

Co-Founder & Chief Operating Officer

Inventor of RITe™ and leader of Orcosa’s technical strategy.

Robert M. Pollaro

Co-Founder & Chief Legal Officer

Guiding legal affairs and intellectual property strategy.

Kevin Kaplan, MD, FAAOS

Chief Medical Officer

Bringing clinical development and sports-medicine expertise.

Andy Drechsler

Chief Financial Officer

Building financial strategy with 30 years of life sciences experience.

Melissa A. Ganchev

Vice President, People Strategy

Developing the people and culture behind Orcosa’s work.

Bryan Ridall

Co-Founder & Chief Executive Officer

Bryan Ridall

Bryan is a Co-Founder and CEO, and has over a decade of experience within the pharmaceutical industry, with a focus on delivery technologies. Before Orcosa, Bryan worked on developing medications for FDA approval with the Center for Veterinary Medicine and led a consulting firm advising emerging pharmaceutical companies.

As the company’s CEO, Bryan’s work at Orcosa has been pivotal to refining our company vision, building partnerships, and executing our strategy. Bryan is responsible for leading operations, driving business development, and optimizing organizational functions to ensure execution of overall business strategy. Bryan holds a B.S. in Business Administration from Villanova University.

Vincent T. Mileto

Co-Founder & Chief Operating Officer

Vincent T. Mileto

Vincent is a Co-Founder and our Chief Operating Officer. A proven leader with over two decades’ worth of pharmaceutical industry experience, he brings a top-to-bottom understanding of how to build and lead Quality Assurance and Operations teams and is a subject matter expert in commercial pharmaceutical manufacturing.

Vincent is responsible for Orcosa’s platform development, manufacturing, engineering, laboratory, and quality assurance business units. His strategic leadership is fundamental to Orcosa’s operational success. His significant experience creating, building, and scaling commercial manufacturing, alongside clinical research, scale-up models, and commercial pharmaceutical launches are critical as the company continues to advance programs through its pipeline.

Robert M. Pollaro

Co-Founder & Chief Legal Officer

Robert M. Pollaro

Robert is a Co-Founder and Chief Legal Officer. Robert has over 20 years of experience as a results-driven lawyer and skilled intellectual property strategist. He has extensive experience advising on complex commercial and intellectual property litigation as well as corporate governance matters.

In his role as EVP and CLO, Robert is responsible for overseeing all aspects of Orcosa’s worldwide legal affairs, including the company’s intellectual property portfolio. Robert’s deep understanding of IP law, and his methodical and vigorous approach to building and protecting the company’s inventions, technologies, and applications are essential to the company’s success.

Prior to joining Orcosa, Robert was Special Counsel at Cadwalader, Wickersham & Taft, specializing in intellectual property litigation for various technology companies. Robert holds a B.S. in Civil and Environmental Engineering from the University of Cincinnati and a J.D. degree from Seton Hall University School of Law.

Kevin Kaplan, MD, FAAOS

Chief Medical Officer

Kevin Kaplan, MD, FAAOS

Dr. Kevin Kaplan brings two decades of elite sports-medicine experience to his post as Chief Medical Officer at Orcosa Inc., where he directs clinical development and regulatory strategy for the company’s novel drug delivery platform. He crafts trial designs, leads FDA interactions, and oversees medical affairs to ensure each program meets the highest standards of safety, efficacy, and scientific rigor.

Dr. Kaplan has served 16 seasons as a physician for the Jacksonville Jaguars including the last 12 years as Head Team Physician, managing player health from injury prevention to surgical care. He is also a leader in the Jacksonville sports community, taking care of high school, collegiate, and professional athletes from numerous teams in the Southeast who request his expertise.

Dr. Kaplan graduated from Tulane University with a Bachelor of Science, majoring in cell and molecular biology and was distinguished as Summa Cum Laude with Honors, Phi Beta Kappa, and a member of numerous National Honors Societies. He attended New York University School of Medicine where he graduated as a Doctor of Medicine and was distinguished in the Alpha Omega Alpha honor society. He completed his orthopaedic residency at NYU Langone – serving as Executive Chief Resident, contributing to over 20 peer-reviewed publications and winning multiple research awards, followed by a sports medicine fellowship at the renowned Kerlan-Jobe Orthopaedic Clinic, where he assisted the 2009 World Champion L.A. Lakers and other professional teams.

Dr. Kaplan is a board certified surgeon with a subspecialty designation in sports medicine and is a fellow of both the American Orthopaedic Society for Sports Medicine and the Arthroscopy Association of North America.

Andy Drechsler

Chief Financial Officer

Andy Drechsler

Andy Drechsler joined Orcosa as Chief Financial Officer (CFO) in May 2026. Andy offers 30 years of financial and operational leadership experience in life sciences companies.

Andy currently serves as acting CFO of Altesa BioSciences, a private clinical stage pharmaceutical focused on infectious respiratory diseases. From 2017 to 2021 Andy served as CFO of Provention Bio (now part of Sanofi), a biopharmaceutical company focused on intercepting and preventing autoimmune diseases like type one diabetes. While at Provention, Andy helped grow the Company from 5 employees to over 80 employees, acquired three development stage programs, and raised over $300 million in equity capital. Andy also served as CFO of Insmed (Nasdaq: INSM) from 2012 to 2017. While at Insmed, Andy helped raise over $400 million via the equity capital markets, helped grow the company from 40 to over 160 people, and established an international infrastructure of six entities operating in the US and the EU. His prior CFO roles also include: VaxInnate Corporation and Valera Pharmaceuticals. He also served as controller for Abbott Laboratories’ Point of Care Division (formerly i-STAT Corporation) and Biomatrix, Inc. (now part of Sanofi).

Andy graduated magna cum laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey.

Andy serves on the Board of Directors of Manasquan Bank and the NJ Chapter of Breakthrough Type One Diabetes.

Melissa A. Ganchev

Vice President, People Strategy

Melissa A. Ganchev

Melissa is our Vice President of People Strategy. As an expert in HR, Melissa brings over 16 years of experience in the Human Resources field, including leading the development of major human resources and talent efforts for a Fortune 200 company prior to joining Orcosa. Melissa holds B.A. from McDaniel College and a Master Certificate in Human Resources Management from Villanova University.

Melissa contributes to the success of Orcosa by developing, implementing, and continually refining our people strategy to ensure that each and every employee is empowered to support the growth and success of the company. She also is responsible for employee compliance and risk policy, and ensuring our culture reflects our mission, values and views of our talented employees. Above all, in collaboration with senior leadership she partners to ensure that we have the RITe people in the RITe place to best serve our organization’s growth.

Advisors & Board

Andrew C. von Eschenbach, MD

Senior Advisor

Former FDA Commissioner
Former Director, National Cancer Institute

Anthony A. Chiurco, MD, FACS

Senior Advisor

Former Chair of Neurosurgery, University Medical Center of Princeton
Former Chairman of Surgery, Capital Health Systems

Robert S. Radie

Independent Board Member

Edward A. Sturchio

Independent Board Member

Andrew C. von Eschenbach, MD

Senior Advisor

Andrew C. von Eschenbach, MD

In his role as Senior Advisor, Dr. von Eschenbach provides strategic counsel on regulatory and public affairs, clinical trial development, and other critical corporate matters.

Dr. von Eschenbach is widely recognized as a leading physician, surgeon, oncologist, and executive. His distinguished career includes serving as Commissioner of the FDA from 2006 to 2009, after being appointed Acting Commissioner in 2005. In that role, he developed and oversaw the FDA’s Critical Path Initiative which aimed at improving the regulatory pathway for drugs and medical devices. Dr. von Eschenbach joined FDA after serving for four years as Director of the National Cancer Institute at the National Institutes of Health, and currently serves on the Board of Directors of the Reagan-Udall Foundation for the FDA.

Dr. von Eschenbach earned a B.S. from St. Joseph’s University and his medical degree from Georgetown University School of Medicine. He served as Lt. Commander in the U.S. Navy Medical Corps. After completing residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he completed a fellowship in urologic oncology at the University of Texas M.D. Anderson Cancer Center.

Anthony A. Chiurco, MD, FACS

Senior Advisor

Anthony A. Chiurco, MD, FACS

In his role as Senior Advisor, Dr. Chiurco provides counsel on business development, pipeline expansion, and investor relations.

Dr. Chiurco led a distinguished 40-year career in neurosurgery and has a successful track record as an angel investor. Dr. Chiurco has served in leadership roles in numerous hospital networks, including Chair of Neurosurgery at University Medical Center of Princeton for over 30 years, and Chairman of Surgery Capital Health Systems, Trenton, NJ.

He has a long association with Thomas Jefferson University, currently serving on the Advisory Board and also as a Member of the President’s Leadership Council of Thomas Jefferson University and Jefferson Health, an 18-hospital system and the largest in the Delaware Valley. He serves as the current Chair, Neuroscience Committee of the Farber Institute of Neuroscience at Thomas Jefferson University and Sidney Kimmel Medical College.

Dr. Chiurco earned a B.S. from St. Joseph’s University and his medical degree from Jefferson Medical College (now Sidney Kimmel Medical College). After completing internship at The Pennsylvania Hospital and residency in neurosurgery at the University of Iowa Hospital and Clinics, he was a research fellow at The University of Pennsylvania prior to entering the private practice of neurosurgery.

Dr. Chiurco is a two-time world champion in the International 12 Metre Class in sailing.

Robert S. Radie

Independent Board Member

Robert S. Radie

Mr. Radie has more than three decades of experience working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. Prior to his current role as Chairman and CEO of Neuraptive Therapeutics, he served as President, CEO and Director of Zyla Life Sciences. His other roles across the life sciences industry include as President and CEO of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur, President and CEO of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, and Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick Pharmaceuticals, he served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company.

He currently serves as Chairman of the Board of Rockwell Medical, and as a member on the Board of Directors of Valsource, Inc. He also serves as Chairman of the Board at Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Previously, Mr. Radie served as a Director of Paratek Pharmaceuticals, Inc., Affinium Pharmaceuticals, Ltd. and Veloxis Pharmaceuticals AS.

Mr. Radie received his B.S. in Chemistry from Boston College.

Edward A. Sturchio

Independent Board Member

Edward A. Sturchio

Mr. Sturchio is an accomplished life sciences executive, business strategist and advisor. Prior to his current role as General Counsel and Executive Committee member of Immatics N.V., he served as General Counsel and Senior Leadership member at Abeona Therapeutics and as Global General Counsel of Advanced Accelerator Applications (AAA), a Novartis company, where he was responsible for worldwide legal, compliance and IP functions across 22 sites in 13 countries. Before joining AAA, Mr. Sturchio worked in the Corporate Securities and Life Sciences departments of Greenberg Traurig LLP and Day Pitney LLP for over fifteen years, where he advised pharmaceutical and life sciences executives and boards of directors on regulatory, transactional, corporate strategy, M&A and securities matters.

He received a J.D. from Seton Hall University and a B.A. in psychology from Villanova University. Mr. Sturchio has written and lectured extensively in the areas of executive leadership, life sciences and corporate securities matters.

Help shape what
comes next.

Careers at Orcosa
Opens in a new tab